Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease
NOVA awarded €2.4 million
to leverage Jinko, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease
Research academic teams of the consortium - Institut de Recherche Saint Louis
1
2 -
to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab
ElsaLys Biotech utilising in silico studies to accelerate the European approval of inolimomab in both adult and paediatric populations with this rare and life-threatening disease
Lyon, France - 19 January 2021: The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery ( NOVA ) and two expert academic teams from Hôpital St Louis (Paris) and Hôpital Henri Mondor (Paris), has been awarded €3.35 million in non-dilutive funding by Bpifrance to
About Faron Pharmaceuticals Ltd Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company s pipeline candidate to prevent vascular leakage and organ failures is currently being te
- Record cash position - Encouraging trial results for ImmunoBON which will be launched in Germany in January 13 January 2021 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the six months ended 31 December 2020 ahead of its Half Year Results to be announced on 3 March 2021. The Group is trading in line with Board expectations, with reported revenues for the six months ended 31 December 2020 having grown to £54.0m (2019: £50.5m), representing 7% growth on a reported basis ( 5% on constant currency basis), despite the challenges of COVID-19. Geographically, there was growth across most major countries with the best performances in Germany, Austria, Netherlands and Switzerland. Sales of Pollinex Quattro and Pollinex continued to progress well, driven by superior technology and a stro
RTW Participates in $75 Million Financing Round in Immunocore
RTW Venture Fund Limited (the Company ), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by its portfolio company Immunocore, Ltd ( Immunocore ) on 11 January 2021 of its completion of a $75 million Series C financing round. The announcement of the financing round comes following positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma that Immunocore presented in December 2020.
The Company, alongside other investment vehicles of RTW Investments, LP (the Investment Manager ), confirms that it participated in the financing round together with other investment firms.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects , anticipates , believes , intends , estimates , plans , will be and similar expressions. Although Sanofi s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict a